RxDoctor Payments Data

Eric Sontz, MD

Cardiovascular Disease · Rancho Mirage, CANPI 1487614798

Payments from drug & device makers

$1,186in general payments, 2019–2025

Across 39 payments — averaging $30.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$411
  • Abiomed$157
  • Abbott$117
  • Novo Nordisk$104
  • Edwards Lifesciences$94
  • Johnson & Johnson$62
  • plus $241 from 6 others

What the payments were for

  • Food & beverage$1,186100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,186 in reported general payments places this provider in the 35th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$1,168,174
Medicare patients
3,574
Services billed
21,008

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban515$695,689
XareltoRivaroxaban195$269,385
JardianceEmpagliflozin125$171,075
EntrestoSacubitril/Valsartan103$134,918
Repatha SureclickEvolocumab129$99,685
OzempicSemaglutide66$77,961
NexlizetBempedoic Acid/Ezetimibe27$25,198
BrilintaTicagrelor15$17,903
Metoprolol Succinate698$12,162
Rosuvastatin Calcium703$10,922
Ezetimibe298$9,368
Atorvastatin Calcium849$8,754
Praluent PenAlirocumab14$7,351
Olmesartan Medoxomil269$6,815
Amlodipine Besylate801$6,109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$62$269,385195 claims
NovartisEntresto$59$134,918103 claims
Novo NordiskOzempic$104$77,96166 claims
Esperion Therapeutics, Inc.Nexlizet$38$25,19827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Rancho Mirage

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →